Predicting response and resistance to cancer immunotherapy

Emerging liquid biopsy biomarkers: Predicting response and resistance to cancer immunotherapy

Speakers: Genevieve Boland, M.D., Ph.D., FACS Massachusetts General HospitalBoston, MA
Evert Jan Van Limbergen, M.D., Ph.D.Maastro Clinic Maastricht, The Netherlands

During the webinar, the speakers:

  • Explain how whole-plasma proteomic profiling in melanoma and non–small cell lung cancer (NSCLC) patients enables the discovery of blood-based biomarkers to predict immunotherapy responses, including resistance and toxicity.
  • Describe how changes in immune activation during immunotherapy and radiation could be tracked by differentially expressed plasma proteins.
  • Clarify how proteomic and transcriptomic biomarkers along with tumor-based analyses can drive patient selection and provide clinically actionable information.
  • Demonstrate the relationship of plasma biomarkers to overall survival and progression-free survival in patients with advanced melanoma undergoing immunotherapy.
    Answer viewer questions during the live broadcast.

To access this webinar, as well as the rest of our categorized library of more than 20 high-quality scientific webinars featuring presentations by leading researchers in their respective fields, please click the button below.